Gain Therapeutics, Inc. (GANX) stock
Close on Nov 13, 2026Market cap $45.39MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $45.39M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.47
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$17.98M
- EPS, diluted
- -$0.43
- Book value per share
- $0.23
- Diluted shares
- 44M
Trading
- Next earnings
- Mar 25, 2027 (estimated, after the close)
- Previous close
- $1.08
- Open
- $1.12
- Day's range
- $1.01 – $1.14
- Volume
- 328,879
- Average volume (20 days)
- 541,424
- Beta (5 years)
- 1.34
- 52-week range
- $0.94 – $4.34
- RSI (14 days)
- 33.8
- Volatility (1 year)
- 101.9%
- Relative volume
- 0.64×
- WACC
- 11.8%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | GANX | S&P 500 | Difference | GANX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.2% | -3.0% | −23.2 pts | ||
| 3 months | -52.0% | -2.8% | −49.2 pts | ||
| Year to date | -67.7% | +11.5% | −79.2 pts | ||
| 1 year | -65.2% | +13.5% | −78.7 pts | ||
| 3 years | -62.7% | +77.7% | −140.4 pts | -28.0% | +21.1% |
| 5 years | -87.4% | +72.6% | −160.0 pts | -33.9% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Gain Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
About Gain Therapeutics
Pharmaceutical Preparations
Gain Therapeutics is a clinical-stage biotechnology company that utilizes its computational discovery platform, Magellan, to identify novel allosteric binding sites on disease-causing proteins. The company focuses on developing small molecule therapeutics, known as structurally targeted allosteric regulators, to treat conditions associated with protein misfolding and dysfunction. Its research and pipeline target central nervous system disorders, lysosomal storage disorders, metabolic diseases, and oncology indications. The company's lead drug candidate, GT-02287, is being developed for the treatment of Parkinson's disease with or without GBA1 mutations. Gain Therapeutics advances its programs and targets through collaborations with academic research institutions and industry licensing or co-development partners.
Company profile, executives and historyGain Therapeutics stock: common questions
What is Gain Therapeutics's stock price?
GANX closed at $1.04 on Nov 13, 2026, down 3.70% on the day. Over the past 52 weeks it traded between $0.94 and $4.34.
What is Gain Therapeutics's market cap?
Gain Therapeutics was worth $45.39M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is GANX's P/E ratio?
Gain Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.43), so it has no meaningful P/E ratio.
Does Gain Therapeutics pay a dividend?
No. Gain Therapeutics has not paid a cash dividend over the last twelve months.
When does Gain Therapeutics report earnings next?
Gain Therapeutics is expected to report Q4 FY2026 results on Mar 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has GANX stock performed over the past year?
Including dividends, GANX returned -65.2% over the past year, against +13.5% for the S&P 500.
How many GANX shares are sold short?
4M shares were sold short at the latest FINRA report, 9.19% of the float, or 5.5 days of average trading volume.
Who are Gain Therapeutics's competitors?
Companies most similar to Gain Therapeutics by business, industry and size include SER, ANVS, ATHE, PRAX, ACIU.
See a number that looks wrong?